Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis

  • First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults
     
  • Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option from ongoing dosing approaches
/by